Get the Daily Brief
Latest Biotech News
Atrium launches with $270M — RNA therapies target rare inherited cardiac disorders
Atrium Therapeutics spun out of Avidity Biosciences with a $270 million launch financing to advance RNA‑based therapeutic candidates for rare inherited cardiomyopathies. The new company inherits...
Merck seeks Welireg label expansion — filings target Keytruda and Lenvima combos
Merck is pursuing regulatory expansions for its HIF‑2α inhibitor Welireg (belzutifan) by seeking approvals for combination regimens with pembrolizumab (Keytruda) and lenvatinib (Lenvima) in kidney...
Health Gorilla fights Epic suit — frames case as attack on interoperability
Health Gorilla moved to dismiss litigation from Epic and several health systems that accuses the company of inappropriate access to nearly 300,000 patient records. In its motion Health Gorilla...
X‑ray‑activated platinum complex boosts radiotherapy and immune response
Researchers reported a platinum‑based complex that becomes active under X‑ray exposure and enhances radiotherapy efficacy by mechanisms distinct from traditional radiosensitizers. Preclinical...
Dual‑receptor knockout amplifies CAR‑T potency against solid tumours
A preclinical study demonstrated that knocking out two prostaglandin E2 (PGE2) receptors in CAR‑T cells markedly improves their activity against solid tumours. The engineered cells showed enhanced...
Viral proteins expose bacterial 'kill switch' — MurJ locked to stop cell‑wall assembly
Scientists discovered that unrelated viruses produce proteins that bind and lock the bacterial membrane flippase MurJ, halting peptidoglycan assembly and triggering bacterial death....
Archaeon reads stop codon as sense codon — rule‑bending genetic code discovered
UC Berkeley scientists reported an archaeon that occasionally translates a canonical stop codon as an amino acid, producing alternate protein isoforms in a context‑dependent manner. The work shows...
Novartis explores Rhapsido for food allergy — Phase 2 shows promising signals
Novartis presented Phase 2 data indicating its recently approved urticaria drug Rhapsido produced favorable immunologic responses in food allergy patients across three dose levels. Company...
Belzutifan–pembrolizumab combo cuts recurrence risk in kidney cancer
A phase 3 trial (LITESPARK-022) reported that adding belzutifan, a HIF‑2α inhibitor, to pembrolizumab significantly improved disease‑free survival in patients with clear‑cell renal cell carcinoma...
FDA to pay bonuses for faster drug reviews — pilot sparks debate
FDA Commissioner Marty Makary announced a pilot program to issue quarterly bonus payments to drug reviewers who complete reviews ahead of schedule, according to slides and a staff presentation...
FDA approves Ascendis' weekly achondroplasia drug — EU decision pending
The FDA approved Ascendis Pharma’s once‑weekly TransCon CNP (navepegritide) for achondroplasia, the company announced; the approval establishes a new branded treatment option for the genetic...
EMA panel backs three orphan drugs — rebuffs two FDA programs
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended three new orphan drugs and declined approval for two programs previously cleared by the FDA, BioCentury...
BioNTech, DualityBio greenlight B7‑H3 ADC into phase 3 — mCRPC race tightens
BioNTech and partner DualityBio advanced their B7‑H3 antibody‑drug conjugate into a phase 3 trial for metastatic castration‑resistant prostate cancer after encouraging phase 1/2 data, the partners...
Atrium spins out with $270M — RNA push for rare heart diseases
Atrium Therapeutics launched with a $270 million financing to advance RNA therapies targeting rare inherited cardiac disorders, MedCity News reported. The spinout emerges from Avidity Biosciences...
Researchers find viral 'kill switch' that locks MurJ: new bacterial target
Researchers discovered that several unrelated viruses produce small proteins that bind and lock the bacterial membrane flippase MurJ into a single conformation, halting peptidoglycan biosynthesis...
Dual receptor knockout enhances CAR‑T activity against solid tumors
Researchers demonstrated that genetically ablating both receptors for prostaglandin E2 (PGE2) in CAR‑T cells markedly enhances their potency against solid tumors in preclinical models. By removing...
GoodRx launches employer program: employers can subsidize GLP‑1s
GoodRx introduced Employer Direct, a program that allows employers to subsidize manufacturer‑sponsored prices for high‑cost brand drugs — explicitly including GLP‑1 weight‑loss therapies — without...
Novartis tests Rhapsido for food allergy...Phase 2 shows dose responses
Novartis presented Phase 2 results testing Rhapsido—an approved drug for chronic hives—in food allergy, reporting that all three doses in the trial produced higher response measures versus...
Moderna wins EU backing: combo flu–COVID vaccine cleared by CHMP
European regulators’ human medicines committee recommended approval of Moderna’s mCombriax, a combined influenza and COVID-19 mRNA vaccine, clearing a major regulatory hurdle for the product in...
BioNTech advances B7-H3 ADC: phase 3 start in prostate cancer
BioNTech and partner DualityBio moved their B7-H3–targeting antibody–drug conjugate into a phase 3 trial for metastatic castration‑resistant prostate cancer (mCRPC) after encouraging phase 1/2...